1. Introduction {#sec1}
===============

Video capsule endoscopy (VCE) is useful in investigating small bowel as well as esophagus, stomach, and colon. Bowel preparation for small bowel VCE is recommended to improve small bowel visualization quality (SBVQ), diagnostic yield (DY), and cecal completion rate (CR). Particularly in the distal small bowel, DY of VCE can be limited due to reduced SBVQ-associated with residual material or dark colored bile. According to a 2009 meta-analysis of 12 studies \[[@B1]\], purgative bowel cleansing prior to VCE improves the SBVQ and increases the DY but does not alter the VCE CR. However, the gastric transit time (GTT) and small bowel transit time (SBTT) of VCE were not affected by purgatives.

We performed online search for VCE bowel preparation-related clinical studies, comparative research, randomized controlled trials (RCTs), meta-analyses, and guidelines published from January 2002 to June 2015. Literature review was conducted using Key MeSH terms of "capsule endoscopy" and "bowel preparation." We also reviewed bowel preparation guidelines for VCE of small bowel based on 2009 European Society of Gastrointestinal Endoscopy (ESGE) guidelines \[[@B2]\], 2013 ESGE guidelines \[[@B3]\], and 2013 Korean guidelines \[[@B4]\] by the Korean Gut Image Study Group, part of the Korean Society of Gastrointestinal Endoscopy. The level of scientific evidence for recommendation was based on study design; for example, the evidence of randomized trial was considered high, observation study was low, and any other type of evidence was very low. The validity of the recommendation was divided into categories of "strong" or "weak" ([Table 1](#tab1){ref-type="table"}) \[[@B5]\]. In this paper, we introduced previous studies on bowel preparation for VCE and suggested optimal preparation methods.

2. Purgatives {#sec2}
=============

2.1. Polyethylene Glycol {#sec2.1}
------------------------

Polyethylene glycol- (PEG-) based regimens are first-line recommendation (Grade A) \[[@B3]\]. The majority of the evidence of bowel preparation prior to small bowel VCE is PEG-based regimens. The 2009 ESGE guidelines recommended purgative bowel preparations in order to enhance small bowel DY by VCE without affecting the CR (category of evidence, 2a; grade of recommendation, B) \[[@B2]\]. According to the Korean Gut Image Study Group guidelines \[[@B4]\], bowel preparation with PEG solution enhances DY and SBVQ, without effect on cecal CR (strong recommendation, moderate quality evidence).

[Table 2](#tab2){ref-type="table"} shows many studies regarding bowel preparation with comparison of PEG versus clear liquid or fasting for small bowel VCE, including prospective randomized controlled trials \[[@B6]--[@B13]\], a prospective blinded nonrandomized trial \[[@B14]\], and a retrospective study \[[@B15]\]. Most studies were performed by comparing SBVQ, DY, and cecal CR between 2 L PEG solution and clear diet or fasting groups. Four-liter PEG solution was used in a few studies \[[@B10], [@B14]\]. In addition, ingestion of a small amount of PEG (500 mL) beginning 30 minutes after swallowing the capsule significantly improves SBVQ and cecal CR, although DY was not affected \[[@B8]\]. Another study regarding a small amount (500 mL) of PEG solution over 2 hours, beginning 30 minutes after swallowing the capsule, showed increased SBVQ without any difference in cecal CR \[[@B12]\]. Since PEG is completely transparent, a view through PEG was considered better than a view through natural intestinal fluid. However, negative result regarding SBVQ with 2 L PEG was reported in one retrospective study \[[@B15]\].

Two-liter PEG solution bowel preparation is similar to that of 4 liters of PEG in DY, SBVQ, and CR of VCE (weak recommendation, moderate quality evidence). Two studies by Kantianis et al. \[[@B16]\] and Park et al. \[[@B11]\] indicated no significant difference between 2 L and 4 L PEG in regard to small bowel cleansing and CR. Therefore, 2 L PEG should be recommended as preparation for VCE, administered on the day prior to the procedure, as the most commonly used preparation method \[[@B17]\].

In colonoscopy, bowel preparation status is classified as excellent, good, fair, poor, or inadequate. Clinically, most gastroenterologists considered excellent and good bowel preparation status as optimal bowel preparation. However, there was no consensus of optimal bowel preparation for VCE, as each study with PEG suggested various definitions for bowel preparation quality ([Table 3](#tab3){ref-type="table"}). A recent study considered excellent or good preparation (\>75% small bowel visualization) as adequate bowel preparation \[[@B13]\]. Therefore, standardized definition of optimal bowel preparation for VCE is necessary.

To date, there has been no consensus regarding optimal timing of bowel preparation for VCE. To evaluate optimal timing of VCE bowel preparation, a single-center randomized controlled trial was conducted by Black et al. \[[@B18]\]. However, there was no significant difference between the quality and timing (day before VCE versus 4 hours prior to VCE) of small bowel preparation. Intestinal lavage administered one day prior was similar to same-day preparation with regard to overall preparation quality, SBTT, frequency of identified mucosal abnormalities, general DY, and CR. One of the issues for bowel preparation of VCE is that the distal segment of the small intestine should be improved. The main limitation of this study is that the number of patients (*n* = 34) is not sufficient for generalizing to actual practice. Therefore, multicenter large randomized controlled trial is required to clarify optimal timing of bowel preparation for VCE.

According to the 2012 consensus guidelines for bowel preparation \[[@B19]\], purgative is absolutely contraindicated in patients with gastrointestinal obstruction, ileus, ulcer, perforation, or inflammatory bowel diseases. In addition, it is also contraindicated in patients with decreased consciousness, swallowing disorders, and hypersensitivity to oral bowel-cleansing agents and in patients having an ileostomy. Therefore, optimal bowel preparation should be made considering individual patient risk factors.

2.2. Sodium Picosulfate {#sec2.2}
-----------------------

Recently, various types of bowel preparation such as PEG, PEG plus ascorbic acid, sodium picosulfate, and phosphate (NaP) are available. There has been no published evidence to support the use of sodium picosulfate; however, it is used in some units. Anecdotal evidence suggests that it is not as effective as PEG \[[@B3]\].

2.3. Sodium Phosphate (NaP) {#sec2.3}
---------------------------

NaP is not recommended for bowel cleansing due to the potential for renal damage and other adverse effects (Grade B) \[[@B3]\]. However, the use of NaP is possible in patients for whom PEG or sodium picosulfate is ineffective or not tolerated (Grade D). According to a previous study conducted using NaP, SBVQ of NaP group is better than overnight fasting (35% versus 4%) \[[@B20]\]. However, recent meta-analysis of NaP-based regimens revealed no significant difference from fasting alone (OR = 1.32, 95% CI = 0.52--2.96, *p* \< 0.0001) \[[@B21]\]. Therefore, NaP should not be used in general.

3. Simethicone {#sec3}
==============

Preparing the small bowel with simethicone has been reported to increase SBVQ by reducing intraluminal air bubbles \[[@B22], [@B23]\]. [Table 4](#tab4){ref-type="table"} demonstrates several studies regarding bowel preparation with simethicone for small bowel VCE \[[@B13], [@B22]--[@B26]\]. Systemic review and meta-analysis of RCTs of simethicone revealed that supplemental use of simethicone prior to VCE enhances SBVQ, especially for patients without purgative, but does not affect the cecal CR \[[@B27]\]. It decreases air bubbles in the colonic lumen but does not improve bowel preparation. Additionally, its effect on DY remains controversial. Bowel preparation by fasting or administration of PEG solution combined with simethicone enhances SBVQ, but it does not affect CR for VCE (strong recommendation, moderate quality evidence) \[[@B4]\].

4. Prokinetics {#sec4}
==============

Prokinetics can be used for shortening of the GTT and may improve cecal CR. To date, various prokinetics including erythromycin \[[@B28]--[@B30]\], mosapride \[[@B31]\], metoclopramide \[[@B32]--[@B34]\], and lubiprostone \[[@B35], [@B36]\] have been investigated for bowel preparation of VCE. [Table 5](#tab5){ref-type="table"} exhibits previous studies regarding bowel preparation with various prokinetics for small bowel VCE. Previously, the battery time of VCE was 8 hours and approximate 20% do not reach the colon due to limited recording time \[[@B34]\]. Currently, the battery time of VCE is about 12 hours; therefore the effect of prokinetics on the CR could be minimal.

Lubiprostone, a selective activator of type 2 chloride channels in the apical membrane of the GI epithelium, as a propulsive agent was investigated for decreasing the SBTT by VCE. However, there were opposite results regarding the GTT and SBTT in two studies \[[@B35], [@B36]\]. Lubiprostone neither decreased the GTT and SBTT nor improved SBVQ for VCE in one double-blind placebo-controlled study \[[@B35]\], while it decreased the SBTT by VCE in another exploratory randomized, double-blind, controlled study \[[@B36]\]. Bowel preparation with prokinetics does not enhance the SBVQ, DY, or CR of VCE. Therefore, it is not generally recommended (weak recommendation, moderate quality evidence) \[[@B4]\].

5. Miscellaneous {#sec5}
================

Recently, there have been new studies using substances such as coffee enema or magnesium citrate. Coffee enema is known to induce dilation of bile ducts and excretion of bile through the colon wall. During VCE, excreted bile is one of the causes of poor bowel preparation. Coffee enema for preparation for small bowel VCE was investigated by a pilot study (*n* = 34) \[[@B37]\]. Comparison of coffee enema plus 2 L PEG versus 2 L PEG demonstrated greater efficacy of bowel preparations in the mid-to-distal segments of the small bowel in patients who received coffee enema plus 2 L PEG than in those who received PEG only. In one magnesium citrate trial of bowel preparation for VCE \[[@B38]\], there was no significant difference between the group that received the preparation (34 g magnesium) and the control group.

6. Conclusion {#sec6}
=============

Bowel preparation is generally recommended for small bowel VCE. Currently, a combination of 2 L PEG and simethicone appears to be the optimal bowel preparation before VCE. After reviewing current articles regarding bowel preparation for VCE, we suggest using purgatives such as PEG as first line and sodium picosulfate as second line with antifoaming agent. However, sodium phosphate should not be used except for the patients whom PEG or sodium picosulfate is not effective and intolerable. However, prokinetics (erythromycin, metoclopramide, or lubiprostone) are not generally recommended. For each of these agents, including purgative (PEG, sodium picosulfate, and sodium phosphate), consensus is needed regarding optimal timing of bowel preparation. Therefore, best bowel preparation is determined considering individual patient status.
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###### 

Quality of evidence and strength of a recommendation.

  Quality of evidence            
  ------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  High quality                   Further research is very unlikely to change our confidence in the estimate of effect.
  Moderate quality               Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
  Low quality                    Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
  Very low quality               Any estimate of effect is very uncertain.
                                 
  Strength of a recommendation   
                                 
  Strong                         Most or all individuals will be best served by the recommended course of action.
  Weak                           Not all individuals will be best served by the recommended course of action. There is a need to consider more carefully than usual individual patient\'s circumstances, preferences, and values.

###### 

Studies comparing SBVQ, DY, and CR between PEG solution versus clear liquid or fasting of small bowel VCE.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author\                          Design                                    Number   PEG versus clear liquid diet or fasting                         
  (year, area)                                                                                                                                        
  -------------------------------- ----------------------------------------- -------- ----------------------------------------- --------------------- ----------------------
  Viazis et al. \[[@B6]\]\         Prospective RCT                           80       90% versus 60%\                           65% versus 30%\       80% versus 65%\
  (2004, Greece)                                                                      *p* = 0.004                               *p* = 0.003           *p* = 0.21

  van Tuyl et al. \[[@B7]\]\       Prospective RCT                           60       72% versus 25%\                           30% versus 27%\       N/A
  (2007, Netherlands)                                                                 *p* = 0.001                               *p* = 0.86            

  Endo et al. \[[@B8]\]^*∗*^ \     Prospective RCT                           59       N/A\                                      78.6% versus 71.6%\   88.9% versus 65.6%\
  (2008, Japan)                                                                       *p* \< 0.01                               *p* = NS              *p* = 0.038

  Wi et al. \[[@B9]\]\             Prospective RCT                           99       56% versus 43%\                           50% versus 39%\       71% versus 75%\
  (2009, Korea)                                                                       *p* = NS                                  *p* = 0.111           *p* = 0.924

  Rey et al. \[[@B10]\]\           Prospective RCT                           116      83.1% versus 38.6%\                       N/A                   N/A
  (2009, France)                                                                      *p* \< 0.05                                                     

  Park et al. \[[@B11]\]\          Prospective RCT                           43       *2.43* versus 2.26\                       65% versus 56.6%\     75% versus 73%\
  (2011, Korea)                                                                       *p* = 0.045                               *p* = NS              *p* = 0.869

  Ito et al. \[[@B12]\]^*∗*^ \     Prospective RCT                           42       4.4 ± 0.8 versus 2.7 ± 1.0\               N/A                   85.0% versus 81.8%\
  (2012, Japan)                                                                       *p* = 0.00004                                                   *p* = 0.89

  Rosa et al. \[[@B13]\]\          Prospective RCT                           60       83.3% versus 65%\                         60% versus 44.4% \    100% versus 88.9%\
  (2013, Portugal)                                                                    *p* = 0.0417                              *p* = 0.587           *p* = 0.312

  Dai et al. \[[@B14]\]\           Prospective blinded nonrandomized trial   61       3.04 versus 2.41\                         N/A                   97% versus 76%\
  (2005, Switzerland)                                                                 *p* \< 0.01                                                     *p* \< 0.01

  Ben-Soussan et al. \[[@B15]\]\   Retrospective study                       42       57.6% versus 62.5%\                       46.2% versus 50.0%\   92.3% versus 100.0%\
  (2005, France)                                                                      *p* = NS                                  *p* = NS              *p* = NS
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PEG: polyethylene glycol, VCE: video capsule endoscopy, RCT: randomized-controlled trial, SBVQ: small bowel visualization quality, DY: diagnostic yield, CR: completion rate, N/A: not applicable, and NS: no significant. ^*∗*^PEG 500 mL.

###### 

Definitions of optimal bowel preparation of VCE among studies with PEG.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author\                          Design                                    Number   Quality of bowel preparation
  (year, area)                                                                        
  -------------------------------- ----------------------------------------- -------- ------------------------------------------------------------------------------------------------------------------------------------
  Viazis et al. \[[@B6]\]\         Prospective RCT                           80       Clean: if \<25% of the mucosal surface was covered by food debris or intestinal contents\
  (2004, Greece)                                                                      Adequate: if the objective score \<10%

  van Tuyl et al. \[[@B7]\]\       Prospective RCT                           60       Good visibility: visualization ≥75% of the mucosa\
  (2007, Netherlands)                                                                 Poor visibility: visualization \<75%

  Endo et al. \[[@B8]\]^*∗*^ \     Prospective RCT                           59       Percentage of visualized bowel surface area\
  (2008, Japan)                                                                       1, \<25%; 2, 25--49%; 3, 50--74%; 4, 75--89%; and 5, \>90%

  Wi et al. \[[@B9]\]\             Prospective RCT                           99       Clean: if \<25% of the mucosal surface was covered by food debris or intestinal contents, concentrated bile, and intraluminal gas\
  (2009, Korea)                                                                       Adequate: if the objective score \<10%

  Rey et al. \[[@B10]\]\           Prospective RCT                           116      Excellent (score 4): imaging of excellent quality, all small lesions, and minor changes of the mucosa could be detected\
  (2009, France)                                                                      Diagnostic (score 3): imaging of sufficient quality to make an accurate diagnosis\
                                                                                      Acceptable (score 2): the imaging quality allows detection of only gross disease, and some small lesions could be missed\
                                                                                      Nondiagnostic (score 1): quality of imaging is poor; it is difficult to make a reliable final diagnosis

  Park et al. \[[@B11]\]\          Prospective RCT                           43       Proportion of visualized mucosa\
  (2011, Korea)                                                                       Score 3, ≥75%; score 2, 50--75%; score 1, 25--50%; score 0, \<25%\
                                                                                      Extent of obscuration by bubbles, debris and bile, and so forth.\
                                                                                      Score 3, \<5%; score 2, 5--25%; score 1, 25--50%; score 0, ≥50%

  Ito et al. \[[@B12]\]^*∗*^ \     Prospective RCT                           42       Percentage of visualized bowel surface area\
  (2012, Japan)                                                                       1, \<25%; 2, 25--49%; 3, 50--74%; 4, 75--89%; and 5, \>90%

  Rosa et al. \[[@B13]\]\          Prospective RCT                           60       Excellent: if an ideal visualization of the small bowel mucosa was achieved\
  (2013, Portugal)                                                                    Good: if \>75% of the mucosa was in perfect condition\
                                                                                      Fair: if only 50%--75% of the mucosa was under perfect conditions\
                                                                                      Poor: if \<50% of the mucosa could be observed \
                                                                                      Adequate: excellent or good preparation

  Dai et al. \[[@B14]\]\           Prospective blinded nonrandomized trial   61       Percentage of visualized bowel wall\
  (2005, Switzerland)                                                                 1, \<25%; 2, 25--49%; 3, 50--75%; 4, \>75%

  Ben-Soussan et al. \[[@B15]\]\   Retrospective study                       42       The presence of biliary secretion, air bubbles, and residue\
  (2005, France)                                                                      1, poor; 2, fair, 3, good; 4, excellent
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PEG: polyethylene glycol, VCE: video capsule endoscopy, and RCT: randomized-controlled trial. ^*∗*^PEG 500 mL.

###### 

Studies comparing SBVQ, DY, and CR between simethicone versus clear liquid or fasting of small bowel VCE.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Author\                     Design            Number   Simethicone versus clear liquid diet or fasting                               
  (year, area)                                                                                                                         
  --------------------------- ----------------- -------- ------------------------------------------------------- --------------------- ---------------------
  Albert et al. \[[@B22]\]\   Prospective RCT   36       72% versus 22%\                                         N/A                   N/A
  (2004, Germany)                                        *p* = 0.001                                                                   

  Ge et al. \[[@B23]\]\       Prospective RCT   56       57% versus 25%\                                         N/A                   64.3% versus 75%\
  (2006, China)                                          *p* = 0.0175                                                                  *p* = NS

                                                                                                                                       

  Author\                     Design            No.      PEG + simethicone versus clear liquid diet or fasting                         
  (year, area)                                                                                                                         

  SBVQ                        DY                CR                                                                                     

                                                                                                                                       

  Fang et al. \[[@B25]\]\     Prospective RCT   64       98% versus 68%\                                         N/A                   N/A
  (2009, China)                                          *p* = 0.001                                                                   

  Spada et al. \[[@B26]\]\    Prospective RCT   58       42% versus 43%\                                         62% versus 72.4%\     66.6% versus 70%\
  (2010, Italy)                                          *p* = 0.86                                              *p* = 0.39            *p* = 0.78

  Rosa et al. \[[@B13]\]\     Prospective RCT   60       68.4% versus 65%\                                       57.8% versus 44.4%\   89.5% versus 88.9%\
  (2013, Portugal)                                       *p* = 0.0417                                            *p* = 0.587           *p* = 0.312
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

PEG: polyethylene glycol, VCE: video capsule endoscopy, RCT: randomized-controlled trial, SBVQ: small bowel visualization quality, DY: diagnostic yield, CR: completion rate, N/A: not applicable, and NS: no significant.

###### 

Studies comparing SBVQ, DY, and CR between prokinetics versus clear liquid or fasting of small bowel VCE.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author\                        Design                            Number   Prokinetics      Prokinetics versus placebo or fasting                                                           
  (year, area)                                                                                                                                                                               
  ------------------------------ --------------------------------- -------- ---------------- --------------------------------------- ----------------- ------------------- ----------------- -----------------
  Leung et al. \[[@B28]\]\       Prospective nonrandomized study   38       Erythromycin     16 versus 70\                           227 versus 183\   54% versus 64%\     N/A               96% versus 79%\
  (2005, China)                                                                              *p* = 0.005                             *p* = 0.18        *p* = 0.74                            *p* = 0.13

  Caddy et al. \[[@B29]\]\       Prospective RCT                   45       Erythromycin     51 versus 38\                           304 versus 302\   1.9 versus 2.2\     N/A               68% versus 78%\
  (2006, Australia)                                                                          *p* = 0.42                              *p* = 0.96        *p* = 0.24                            *p* = 0.45

  Niv et al. \[[@B30]\]\         Retrospective\                    100      Erythromycin     21 versus 28\                           279 versus 270\   2.8 versus 2.8\     48% versus 36%\   90% versus 84%\
  (2008, Israel)                 blind study                                                 *p* = 0.07                              *p* = 0.83        *p* = 0.73          *p* = N/A         *p* = 0.37

  Wei et al. \[[@B31]\]\         Prospective RCT                   60       Mosapride        14 versus 34\                           248 versus 281\   N/A                 73% versus 50%\   93% versus 67%\
  (2007, China)                                                                              *p* = 0.035                             *p* = 0.3492                          *p* = 0.110       *p* = 0.021

  Selby \[[@B32]\]\              Prospective RCT                   150      Metoclopramide   31 versus 48\                           231 versus 256\   100% versus 69%\    51% versus 57%\   97% versus 76%\
  (2005, Australia)                                                                          *p* = 0.025                             *p* = 0.35        *p* = 0.998         *p* = N/A         *P* \< 0.001

  Postgate et al. \[[@B33]\]\    Prospective RCT                   74       Metoclopramide   17 versus 17\                           260 versus 278\   38 versus 37\       26% versus 35%\   85% versus 89%\
  (2009, UK)                                                                                 *p* = 0.62                              *p* = 0.91        *p* = 0.18          *p* = 0.45        *p* = 0.74

  Almeida et al. \[[@B34]\]\     Prospective RCT                   95       Metoclopramide   26 versus 28\                           221 versus 256\   55% versus 54%\     68% versus 65%\   81% versus 77%\
  (2010, Portugal)                                                                           *p* = 0.511                             *p* = 0.083       *p* = 0.545         *p* = 0.443       *p* = 0.422

  Hooks III et al. \[[@B35]\]\   Prospective RCT                   40       Lubiprostone     126 versus 43\                          188 versus 219\   NS                  N/A               N/A
  (2009, Netherlands)                                                                        *p* = 0.0095                            *p* = 0.130                                             

  Matsuura et al. \[[@B36]\]\    Prospective RCT                   6        Lubiprostone     58 versus 23\                           111 versus 179\   3.76 versus 2.88\   N/A               N/A
  (2014, Japan)                                                                              *p* = 0.846                             *p* = 0.042       *p* \< 0.001                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

VCE: video capsule endoscopy, GTT: gastric transit time, SBTT: small bowel transit time, SBVQ: small bowel visualization quality, DY: diagnostic yield, CR: completion rate, RCT: randomized controlled trial, N/A: not applicable, and NS: no significant.
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